Literature DB >> 34021414

Laparoscopic biopsy and staging for locally advanced pancreatic cancer: experiences of 76 consecutive patients in a single institution.

Xianchao Lin1, Ronggui Lin1, Fengchun Lu1, Yuanyuan Yang1, Congfei Wang1, Haizong Fang1, Yanchang Chen1, Heguang Huang2.   

Abstract

BACKGROUND: Pathological diagnosis plays a critical role in the treatment of locally advanced pancreatic cancer (LAPC). However, the commonly used biopsy methods still have a number of shortcomings, such as a relatively low diagnostic accuracy and a high incidence of complications.
METHODS: A retrospective review was conducted to compare 76 patients with laparoscopic biopsy and staging and 11 patients with CT-guided pancreatic biopsy for LAPC between January 2017 and October 2020. Logistic regression with univariate and multivariate analyses was performed to identify preoperative predictors of occult metastasis.
RESULTS: The diagnostic accuracy of laparoscopic biopsy and staging for pancreatic cancer was 100%. Sixty-two patients were confirmed to have LAPC, 59 patients by pancreatic biopsy and three patients by regional lymph node biopsy. Fourteen patients were diagnosed with distant occult metastasis, three patients by liver biopsy and 11 patients by peritoneum biopsy. Nine patients with severe obstructive manifestations underwent a simultaneous bypass procedure. No postoperative hemorrhage, pancreatic fistula, intra-abdominal infection, or trocar site metastasis was observed. Laparoscopic biopsy and staging had a higher diagnostic accuracy (100% vs. 81.8%, p=0.0147) and a shorter duration to chemotherapy (3 days vs. 9 days, p=0.035) than CT-guided biopsy. Elevated CA125 levels (≥35 U/ml) were a significant preoperative predictor of occult metastasis (OR 6.482, 95% CI 1.624-25.874, p=0.008).
CONCLUSIONS: Laparoscopic biopsy and staging are safe and effective methods to obtain rapid pathology and precise staging for LAPC patients, especially for patients with elevated CA125 levels.

Entities:  

Keywords:  Biopsy; Laparoscopic; Pancreatic cancer; Staging

Year:  2021        PMID: 34021414     DOI: 10.1007/s00423-021-02199-5

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  23 in total

Review 1.  Pancreatic cancer.

Authors:  Jonathan D Mizrahi; Rishi Surana; Juan W Valle; Rachna T Shroff
Journal:  Lancet       Date:  2020-06-27       Impact factor: 79.321

2.  Percutaneous Pancreatic Biopsies-Still an Effective Method for Histologic Confirmation of Malignancy.

Authors:  Imran Bhatti; Dotun Ojo; Ashley R Dennison; Yvonne Rees; Mosheir Elabassy; Giuseppe Garcea
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2016-08       Impact factor: 1.719

3.  Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.

Authors:  Thilo Hackert; Milena Sachsenmaier; Ulf Hinz; Lutz Schneider; Christoph W Michalski; Christoph Springfeld; Oliver Strobel; Dirk Jäger; Alexis Ulrich; Markus W Büchler
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

Review 4.  The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After.

Authors:  Claudio Bassi; Giovanni Marchegiani; Christos Dervenis; Micheal Sarr; Mohammad Abu Hilal; Mustapha Adham; Peter Allen; Roland Andersson; Horacio J Asbun; Marc G Besselink; Kevin Conlon; Marco Del Chiaro; Massimo Falconi; Laureano Fernandez-Cruz; Carlos Fernandez-Del Castillo; Abe Fingerhut; Helmut Friess; Dirk J Gouma; Thilo Hackert; Jakob Izbicki; Keith D Lillemoe; John P Neoptolemos; Attila Olah; Richard Schulick; Shailesh V Shrikhande; Tadahiro Takada; Kyoichi Takaori; William Traverso; Charles R Vollmer; Christopher L Wolfgang; Charles J Yeo; Roberto Salvia; Marcus Buchler
Journal:  Surgery       Date:  2016-12-28       Impact factor: 3.982

5.  Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Edward P Balaban; Pamela B Mangu; Alok A Khorana; Manish A Shah; Somnath Mukherjee; Christopher H Crane; Milind M Javle; Jennifer R Eads; Peter Allen; Andrew H Ko; Anitra Engebretson; Joseph M Herman; John H Strickler; Al B Benson; Susan Urba; Nelson S Yee
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

6.  Image-Guided Percutaneous Biopsy for Pancreatic Lesions: 10-Year Experience in a Tertiary Cancer Center.

Authors:  Steffan Frosi Stella; Mathias Van Borsel; George Markose; Sabarinath B Nair
Journal:  Can Assoc Radiol J       Date:  2019-03-17       Impact factor: 2.248

7.  EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis.

Authors:  Michael Jonathan Hewitt; Mark J W McPhail; Lucia Possamai; Ameet Dhar; Panagiotis Vlavianos; Kevin J Monahan
Journal:  Gastrointest Endosc       Date:  2012-02       Impact factor: 9.427

8.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

9.  Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer.

Authors:  Saowanee Ngamruengphong; Kristi M Swanson; Nilay D Shah; Michael B Wallace
Journal:  Gut       Date:  2015-01-09       Impact factor: 23.059

10.  EUS-guided fine needle biopsy of pancreatic masses can yield true histology.

Authors:  Ji Young Bang; Shantel Hebert-Magee; Udayakumar Navaneethan; Muhammad K Hasan; Robert Hawes; Shyam Varadarajulu
Journal:  Gut       Date:  2017-10-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.